Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 280 | 56 | 222 |
| Samples | 264 | 53 | 209 |
| Peptides | 214 | 44 | 177 |
Function
LMNB2 · Lamin B2
This gene encodes a B type nuclear lamin. The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Mutations in this gene are associated with acquired partial lipodystrophy. [provided by RefSeq, May 2012].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000325327 | Q03252 | 280 | 214 |
Gene Properties
Recurrent Mutations
All 213 amino-acid changes on canonical ENST00000325327 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LMNB2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LMNB2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 10/612 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 11/752 1% |
| Colorectal Carcinoma | 9/143 6% | 35/3239 1% |
| Ewings Sarcoma | 2/63 3% | 2/262 1% |
| Bladder Carcinoma | 1/58 2% | 11/956 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Melanoma | 4/210 2% | 17/1899 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 10/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Head and Neck Carcinoma | 1/85 1% | 12/1574 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Other Solid Cancers | 1/94 1% | 11/1515 1% |
| Gastric Carcinoma | 0/74 0% | 14/1809 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Neuroendocrine Tumour | 4/154 3% | 0/577 0% |
| Glioma | 0/52 0% | 11/2127 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Neuroblastoma | 5/87 6% | 0/1331 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Other Sarcomas | 1/69 1% | 1/699 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
Mutation Distribution
Where LMNB2 is mutated · all tissues, split by cell line vs tissue
How many mutations in LMNB2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 280 mutations in LMNB2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|